Medical - Devices · NYSE
Current Price
$69.13
Intrinsic Value
Use the calculator below to estimate
Run a PE ratio stock valuation on Boston Scientific Corporation with auto-filled earnings data, adjustable target PE, and instant fair value estimate.
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Earnings Yield
2.82%
ROE (TTM)
12.5%
Based on trailing twelve-month data, BSX has earnings per share of N/A and trades at a PE ratio of N/A. These are key inputs for stock valuation using the PE ratio method.
The trailing twelve-month PE ratio of BSX is available in the calculator. This stock valuation metric shows how much investors pay per dollar of Boston Scientific Corporation's earnings. Use MiniValuator's PE ratio calculator for detailed analysis.
Whether BSX is overvalued depends on comparing its PE ratio to industry peers, historical averages, and growth expectations. A PE ratio above the sector average may indicate overvaluation, but high-growth companies often justify higher PE ratios. Run a full stock valuation on MiniValuator to analyze.
To value BSX using PE ratio: compare its current PE to the sector average, analyze the PEG ratio for growth-adjusted stock valuation, check historical PE ranges, and estimate fair value by multiplying target PE by EPS. MiniValuator's PE ratio calculator automates this analysis.
The PEG ratio of BSX is available in the calculator. PEG ratio divides the PE ratio by the earnings growth rate — a PEG below 1.0 may suggest the stock is undervalued relative to its growth, making it a useful complementary stock valuation metric.
PE ratio provides quick relative stock valuation — how BSX compares to peers. DCF provides absolute stock valuation — what the stock is worth based on projected cash flows. For comprehensive stock valuation, use both methods together. MiniValuator offers both PE and DCF calculators.
